Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Prevalence of Plasma Lipid Abnormalities and Associated Risk Factors Among Iranian Adults Based on the Findings From Steps Survey 2021 Publisher Pubmed



Khanali J1, 2 ; Ghasemi E1 ; Rashidi MM1 ; Ahmadi N1 ; Ghamari SH1 ; Azangoukhyavy M1, 2 ; Malekpour MR1 ; Abbasikangevari M1 ; Hashemi SM1 ; Naderian M1, 3 ; Rezaei N1 ; Dilmaghanimarand A1 ; Farzi Y1 ; Kazemi A1 Show All Authors
Authors
  1. Khanali J1, 2
  2. Ghasemi E1
  3. Rashidi MM1
  4. Ahmadi N1
  5. Ghamari SH1
  6. Azangoukhyavy M1, 2
  7. Malekpour MR1
  8. Abbasikangevari M1
  9. Hashemi SM1
  10. Naderian M1, 3
  11. Rezaei N1
  12. Dilmaghanimarand A1
  13. Farzi Y1
  14. Kazemi A1
  15. Yoosefi M1, 4
  16. Hajebi A1
  17. Rezaei S1, 5
  18. Azadnajafabad S1
  19. Fattahi N1, 6
  20. Nasserinejad M1, 7
  21. Abdolhamidi E1
  22. Haghshenas R1
  23. Rezaei N1
  24. Djalalinia S8
  25. Larijani B9
  26. Farzadfar F1, 9
Show Affiliations
Authors Affiliations
  1. 1. Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Second Floor, No.10, Jalal Al-e-Ahmad Highway, Tehran, 1411713137, Iran
  2. 2. Social Determinants of Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. 3. Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Mathematics and Statistics, Memorial University of Newfoundland, St. John’s, NL, Canada
  5. 5. Human Nutrition Program, Department of Human Sciences, The Ohio State University, Columbus, OH, United States
  6. 6. Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States
  7. 7. Center for Life Course Health ResearchFaculty of Medicine, University of Oulu, Oulu, Finland
  8. 8. Development of Research and Technology Center, Deputy of Research and Technology, Ministry of Health and Medical Education, Tehran, Iran
  9. 9. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

Source: Scientific Reports Published:2023


Abstract

The study aimed to estimate the prevalence of lipid abnormalities in Iranian adults by demographic characterization, geographical distribution, and associated risk factors using national and sub-national representative samples of the STEPs 2021 survey in Iran. In this population-based household survey, a total of 18,119 individuals aged over 25 years provided blood samples for biochemical analysis. Dyslipidemia was defined by the presence of at least one of the lipid abnormalities of hypertriglyceridemia (≥ 150 mg/dL), hypercholesterolemia (≥ 200 mg/dL), high LDL-C (≥ 130 mg/dL), and low HDL-C (< 50 mg/dL in women, < 40 mg/dL in men), or self-reported use of lipid-lowering medications. Mixed dyslipidemia was characterized as the coexistence of high LDL-C with at least one of the hypertriglyceridemia and low HDL-C. The prevalence of each lipid abnormality was determined by each population strata, and the determinants of abnormal lipid levels were identified using a multiple logistic regression model. The prevalence was 39.7% for hypertriglyceridemia, 21.2% for hypercholesterolemia, 16.4% for high LDL-C, 68.4% for low HDL-C, and 81.0% for dyslipidemia. Hypercholesterolemia and low HDL-C were more prevalent in women, and hypertriglyceridemia was more prevalent in men. The prevalence of dyslipidemia was higher in women (OR = 1.8), obese (OR = 2.8) and overweight (OR = 2.3) persons, those residents in urban areas (OR = 1.1), those with inappropriate physical activity (OR = 1.2), patients with diabetes (OR = 2.7) and hypertension (OR = 1.9), and participants with a history (OR = 1.6) or familial history of CVDs (OR = 1.2). Mixed dyslipidemia prevalence was 13.6% in women and 11.4% in men (P < 0.05). The prevalence of lipid abnormalities was highly heterogeneous among provinces, and East Azarbaijan with 85.3% (81.5–89.1) and Golestan with 68.5% (64.8–72.2) had the highest and lowest prevalence of dyslipidemia, respectively. Although the prevalence of high cholesterol and LDL-C had a descending trend in the 2016–2021 period, the prevalence of dyslipidemia remained unchanged. There are modifiable risk factors associated with dyslipidemia that can be targeted by the primary healthcare system. To modify these risk factors and promote metabolic health in the country, action plans should come to action through a multi-sectoral and collaborative approach. © 2023, Springer Nature Limited.
Other Related Docs
21. The Slums in the Mirror of Health: A Systematic Review Analysis From Iran, International Journal of Preventive Medicine (2022)
35. National and Subnational Burden of Stroke in Iran From 1990 to 2019, Annals of Clinical and Translational Neurology (2022)
39. Policy Implications for Diabetes Prevention and Control: An Experience From Iran, Medical Journal of the Islamic Republic of Iran (2022)